Early trial checks safety of experimental cancer drug
NCT ID NCT05148325
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information for future trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing cancer hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Can new drug cocktails reawaken the immune system against melanoma?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Can a protein calm the immune System's overreaction to cancer treatment?